» Articles » PMID: 16691196

Serine Protease Signaling of Epidermal Permeability Barrier Homeostasis

Overview
Publisher Elsevier
Specialty Dermatology
Date 2006 May 13
PMID 16691196
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Evidence is growing that protease-activated receptor-2 (PAR-2) plays a key role in epithelial inflammation. We hypothesized here that PAR-2 plays a central role in epidermal permeability barrier homeostasis by mediating signaling from serine proteases (SP) in the stratum corneum (SC). Since the SC contains tryptic- and chymotryptic-like activity, we assessed the influence of SP activation/inhibition on barrier function. Acute barrier disruption increases SP activity and blockade by topical SP inhibitors (SPI) accelerates barrier recovery after acute abrogation. This improvement in barrier function is due to accelerated lamellar body (LB) secretion. Since tryptic SP signal certain downstream responses through PAR-2, we assessed its potential role in mediating the negative effects of SP on permeability barrier. Firstly, PAR-2 is expressed in the outer nucleated layers of the epidermis and most specifically under basal condition to the lipid raft (LR) domains. Secondly, tape stripping-induced barrier abrogation provokes PAR-2 activation, as shown by receptor internalization (i.e. receptor movement from LR to cytolpasmic domains). Thirdly, topical applications of PAR-2 agonist peptide, SLIGRL, delay permeability barrier recovery and inhibit LB secretion, while, conversely, PAR-2 knockout mice display accelerated barrier recovery kinetics and enhanced LB secretion, paralleled by increased LR formation and caveolin-1 expression. These results demonstrate first, the importance of SP/SPI balance for normal permeability barrier homeostasis, and second, they identify PAR-2 as a novel signaling mechanism of permeability barrier, that is, of response linked to LB secretion.

Citing Articles

The Therapeutic Potential of Kiwi Extract as a Source of Cysteine Protease Inhibitors on DNCB-Induced Atopic Dermatitis in Mice and Human Keratinocyte HaCaT Cells.

Yang H, Zahan M, Hwang D, Prakash R, Ravi D, Hong I Int J Mol Sci. 2025; 26(4).

PMID: 40004009 PMC: 11855533. DOI: 10.3390/ijms26041534.


Update on protease-activated receptor 2 in inflammatory and autoimmune dermatological diseases.

Xu K, Wang L, Lin M, He G Front Immunol. 2024; 15:1449126.

PMID: 39364397 PMC: 11446762. DOI: 10.3389/fimmu.2024.1449126.


Protease-Activated Receptor 2 in inflammatory skin disease: current evidence and future perspectives.

Fan M, Fan X, Lai Y, Chen J, Peng Y, Peng Y Front Immunol. 2024; 15:1448952.

PMID: 39301020 PMC: 11410643. DOI: 10.3389/fimmu.2024.1448952.


Efficacy of Topical Application of a Skin Moisturizer Containing Pseudo-Ceramide and a Eucalyptus Leaf Extract on Atopic Dermatitis: A Review.

Takagi Y J Clin Med. 2024; 13(6).

PMID: 38541973 PMC: 10970882. DOI: 10.3390/jcm13061749.


Skin Barrier Function: The Interplay of Physical, Chemical, and Immunologic Properties.

Baker P, Huang C, Radi R, Moll S, Jules E, Arbiser J Cells. 2023; 12(23).

PMID: 38067173 PMC: 10706187. DOI: 10.3390/cells12232745.